U.K. May Retain Value-Based Pricing, Even If Health Care Bill Fails
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.
The U.K.’s Health and Social Care Bill is struggling in parliament, but even if it falls, the government’s plans for value-based drug pricing may survive.